Clinicogenomic profile and progression patterns in lung squamous cell carcinoma treated with immune checkpoint inhibitors.

作者：Lingzhi Hong, Yanhua Tian, Maricel Corredor, Sidi Z. Swift, Hui Li, Frank Rojas Alvarez, Waree Rinsurongkawong, Elliana Young, Don L. Gibbons, Ara A. Vaporciyan, J. Jack Lee, Sinchita Roy-Chowdhuri, Mark Routbort, Xiuning Le, Yasir Y. Elamin, Natalie I. Vokes, J Heymach, Luisa M. Solis, Nicholas Navin, J Zhang · 发表于：Journal of Clinical Oncology · 年份：2026 · DOI：10.1200/jco.2026.44.16_suppl.e20593 · 研究领域：Cancer Immunotherapy and Biomarkers、Ferroptosis and cancer prognosis、Lung Cancer Research Studies

e20593 Background: Lung squamous cell carcinoma (LUSC) is associated with inferior outcomes to immune-checkpoint inhibitors (ICIs), compared to lung adenocarcinoma. However, the underlying mechanisms of ICI resistance in LUSC remain poorly understood. Methods: The GEMINI database was queried to identify advanced or metastatic LUSC patients who were treated with ICI or in combination with chemotherapy (ICI-chemo). Clinical pathologic, genomic, and outcome data were extracted. PD-L1, TMB, standard of care genomic, and Xenium data on patient tumor samples were analyzed. Results: A total of 569 patients with LUSC treated with ICIs were identified, including 421 in the first-line setting. Overall, 66.5% were male, and 91% were smokers. At baseline, 290 (51%) patients had intrathoracic disease, while 279 (49%) had distant metastasis, including 90 with liver involvement and 71 with brain metastases. The overall response rate was 34%, with a median PFS of 6.5 months (95%CI, 5.9 – 7.3) and a median OS of 19.3 months (95%CI, 16.5 – 22.3). Median PFS was 3.5 months (95%CI, 2.5 – 4.9) for cases with liver metastases, and 5.1 months (95%CI 4.0 – 12.2) for those with brain metastases. Among the 420 cases with progression disease, 256 were limited to baseline organs, 55 involved new organ sites excluding the liver or brain, and 109 had progression in the liver or brain. Patients with liver or brain progression had the worst PFS and OS (p < 0.0001) compared to other progression patterns. ...